SKF 83566 hydrobromide
Potent and selective D1-like dopamine receptor antagonist (Ki~ 0.56 nM for D1; KB = 2 μM for D2). Also antagonist at the vascular 5-HT2 receptor (Ki = 11 nM). Displays selective inhibition of adenylyl cyclase 2 (AC2); inactive against AC1 or AC5. Centrally active following systemic administration in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||10.33||25mM with gentle warming|
|water||2.07||5mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 413.15. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.42 mL||12.1 mL||24.2 mL|
|5 mM||0.48 mL||2.42 mL||4.84 mL|
|10 mM||0.24 mL||1.21 mL||2.42 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
References are publications that support the products' biological activity.
Fritts et al (1998) Locomotor stereotypy produced by dexbenzetimide and scopolamine is reduced by SKF 83566, not sulpiride. Pharmacol.Biochem.Behav. 60 639 PMID: 9678647
Meyer et al (1993) Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol.Biochem.Behav. 44 429 PMID: 8446676
Ohlstein and Berkowitz (1985) SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur.J.Pharmacol. 108 205 PMID: 3884345
Conley et al (2013) Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J.Pharmacol.Exp.Ther. 347 276 PMID: 24008337
If you know of a relevant reference for SKF 83566 hydrobromide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SKF 83566 hydrobromide, supplier, Potent, selective, D1-like, antagonists, Dopamine, Receptors, D5, dopaminergic, SKF83566, hydrobromide, D1, and, D5, Receptors, Adenylyl, Cyclase, D1, and, D5, Receptors, Tocris Bioscience
6 Citations for SKF 83566 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 83566 hydrobromide include:
Belinsky et al (2013) Dopamine receptors in human embryonic stem cell neurodifferentiation. Stem Cells Dev 22 1522 PMID: 23286225
Billes et al (2012) Leptin reduces food intake via a dopamine D2 receptor-dependent mechanism. Mol Metab 1 86 PMID: 24024122
Liu et al (2008) Increased dopamine level enhances male-male courtship in Drosophila. World J Gastroenterol 28 5539 PMID: 18495888
Xing et al (2015) Dopamine D1 receptor activation regulates the expression of the estrogen synthesis gene aromatase B in radial glial cells. Hum Mol Genet 9 310 PMID: 26388722
Cassar et al (2015) A dopamine receptor contributes to paraquat-induced neurotoxicity in Drosophila. Learn Mem 24 197 PMID: 25158689
Savalli et al (2015) Regionally selective requirement for D1/D5 dopaminergic neurotransmission in the medial prefrontal cortex in object-in-place associative recognition memory. J Neurosci 22 69 PMID: 25593292
Do you know of a great paper that uses SKF 83566 hydrobromide from Tocris? If so please let us know.
SKF 83566 hydrobromide Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.